We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-14.64%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.19B
AUM Growth
-$126M
Cap. Flow
+$122M
Cap. Flow %
10.23%
Top 10 Hldgs %
29.08%
Holding
134
New
12
Increased
77
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.7M
2
WBA
Walgreens Boots Alliance
WBA
+$9.86M
3
ALKS icon
Alkermes
ALKS
+$7.68M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.42M
5
RDUS
Radius Health, Inc.
RDUS
+$7.3M

Top Sells

Rank Stock Value
1
IDXX icon
Idexx Laboratories
IDXX
+$9.3M
2
RLYP
RELYPSA INC COM
RLYP
+$7.14M
3
ABBV icon
AbbVie
ABBV
+$5.18M
4
DYAX
DYAX CORPORATION
DYAX
+$4.67M
5
TVTX icon
Travere Therapeutics
TVTX
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 77.87%
2 Financials 3.87%
3 Industrials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
26
Amgen
AMGN
$222B
$14.1M 1.18%
94,000
+13,100
+16% +$1.95M
BIIB icon
27
Biogen
BIIB
$30.7B
$13.8M 1.16%
53,150
+2,500
+5% +$660K
PRTA icon
28
Prothena Corp
PRTA
$450M
$12.7M 1.06%
308,000
+60,000
+24% +$2.35M
MD icon
29
Pediatrix Medical
MD
$2.2B
$12.6M 1.06%
195,000
+2,000
+1% +$133K
TBPH icon
30
Theravance Biopharma
TBPH
$877M
$12.2M 1.02%
650,500
+5,500
+0.9% +$90K
MCK icon
31
McKesson
MCK
$101B
$12.2M 1.02%
77,500
+5,000
+7% +$808K
JAZZ icon
32
Jazz Pharmaceuticals
JAZZ
$16.7B
$11.2M 0.94%
85,500
+5,200
+6% +$647K
BMY icon
33
Bristol-Myers Squibb
BMY
$132B
$10.9M 0.91%
+170,000
New +$10.7M
PRAH
34
DELISTED
PRA Health Sciences, Inc.
PRAH
$10.8M 0.91%
253,000
– –
GWPH
35
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$10.6M 0.89%
147,000
+31,000
+27% +$1.7M
PEN icon
36
Penumbra
PEN
$12.8B
$10.5M 0.88%
228,500
+23,500
+11% +$1.1M
WBA
37
DELISTED
Walgreens Boots Alliance
WBA
$10.4M 0.87%
+123,500
New +$9.86M
TXMD icon
38
TherapeuticsMD
TXMD
$24M
$10.1M 0.84%
31,500
+7,800
+33% +$2.66M
ANAC
39
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$9.49M 0.79%
177,500
+100,500
+131% +$7.42M
INCY icon
40
Incyte
INCY
$24.4B
$9.46M 0.79%
130,500
+3,500
+3% +$261K
ACHN
41
DELISTED
Achillion Pharmaceuticals
ACHN
$9.42M 0.79%
1,220,000
+115,000
+10% +$842K
LKFT
42
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$8.78M 0.74%
210,000
– –
BMRN icon
43
BioMarin Pharmaceuticals
BMRN
$12.4B
$8.52M 0.71%
103,250
+33,250
+48% +$2.71M
ARDX icon
44
Ardelyx
ARDX
$997M
$8.24M 0.69%
1,060,400
+377,900
+55% +$3.72M
WMGI
45
DELISTED
Wright Medical Group Inc
WMGI
$8.13M 0.68%
490,000
+34,000
+7% +$630K
INOV
46
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
$7.91M 0.66%
427,300
-50,000
-10% -$883K
EHC icon
47
Encompass Health
EHC
$12.4B
$7.83M 0.66%
261,456
+16,341
+7% +$451K
NVTA
48
DELISTED
Invitae Corporation
NVTA
$7.7M 0.65%
752,500
+129,600
+21% +$1.03M
JUNO
49
DELISTED
Juno Therapeutics, Inc.
JUNO
$7.5M 0.63%
197,001
– –
RARE icon
50
Ultragenyx Pharmaceutical
RARE
$2.55B
$7.5M 0.63%
118,500
+13,000
+12% +$851K
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Rock Springs Capital Management held 134 positions worth $1.19B, down 9.6% from $1.32B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $122M of net new capital in Q1 2016, opening 12 new positions and adding to 77 existing holdings. Its largest new stake was Bristol-Myers Squibb: 170,000 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $2.33M trimmed.

  • Rock Springs Capital Management's largest Q1 2016 buy was Bristol-Myers Squibb: 170,000 shares worth $10.9M.
  • Rock Springs Capital Management added most to ANACOR PHARMACEUTICALS INC COM in Q1 2016, an estimated $7.42M increase.
  • Rock Springs Capital Management's biggest Q1 2016 reduction was Travere Therapeutics, cutting an estimated $2.33M.
  • Rock Springs Capital Management fully exited Idexx Laboratories in Q1 2016, selling an estimated $9.3M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.19B portfolio in Q1 2016.
  • Rock Springs Capital Management opened 12 new positions and closed 6 in Q1 2016.
  • Rock Springs Capital Management's portfolio value fell 9.6% quarter-over-quarter to $1.19B.

Based on Rock Springs Capital Management's 13F filing for Q1 2016, filed 16 May 2016.